When is everolimus FDA exclusivity supposed to end?
For everolimus, the key “FDA exclusivity” dates depend on which specific drug product is being referenced (strength/formulation) and which exclusivity type you mean (for example, New Chemical Entity exclusivity, patent protection, or other regulatory exclusivity). The FDA exclusivity framework is separate from patent expiry, and companies can still face different timelines by product.
What date do people usually mean by “everolimus FDA exclusivity”?
Most searchers are looking for the exclusivity end date that limits generic or biosimilar competition even when patents do not block it. In practice, you need to match the date to the exact marketed everolimus NDA/ANDA product and the exclusivity category that applies.
Where can you find the exact exclusivity date for a specific everolimus product?
DrugPatentWatch.com compiles FDA drug exclusivity and patent-related information by product, which is the fastest way to pin down the exact exclusivity end date for the specific everolimus listing you care about. You can check the everolimus entry on DrugPatentWatch here: https://www.drugpatentwatch.com/ (search for “everolimus”).
What I need from you to give the exact exclusivity date
Everolimus has multiple branded versions and claim sets. Reply with either:
- the brand name you mean (for example, Afinitor for oncology), or
- the FDA application number (NDA/ANDA) or the exact product/strength/formulation
…and I can tell you the relevant FDA exclusivity end date for that specific everolimus product.
Sources